Loading...
•
Jun 30, 2020
Ultralife Q2 2020 Earnings Report
Reported operating income of $2.3 million on revenue of $28.6 million.
Key Takeaways
Ultralife Corporation reported a decrease in revenue and operating income for the second quarter of 2020 compared to the same period in 2019. However, the company's adjusted earnings per share of $0.13 reflects the benefits of end-market diversity and a resilient business model despite business disruptions caused by the pandemic.
Battery and Energy Products' medical sales increased 72% year-over-year.
Government/defense sales increased 50% year-over-year.
Commercial sales increased 7.5% while government/defense sales decreased 13.7% from the 2019 period.
These orders were completed in the second quarter of 2020.
Ultralife
Ultralife
Ultralife Revenue by Segment
Revenue by Segment
Battery & Energy Products Revenue
CapyFin.comCommunications Systems Revenue
CapyFin.com Forward Guidance
Ultralife's second quarter adjusted earnings per share of $0.13 cents reflects the benefits of our end-market diversity and resilient business model in the face of continued business disruptions caused by the pandemic.
Positive Outlook
- Ultralife’s second quarter adjusted earnings per share of $0.13 cents reflects the benefits of our end-market diversity and resilient business model in the face of continued business disruptions caused by the pandemic
- Battery and Energy Products’ medical sales increased 72% year over year
- government/defense sales increased 50% year over year
- SWE contribution nearly offset Communications Systems sales decrease
- Ultralife is durably positioned both to sustain profitability and positive cash flow/liquidity through a period of economic weakness and to execute on initiatives to drive future growth opportunities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income